[HTML][HTML] Recent updates on GLP-1 agonists: Current advancements & challenges
D Sharma, S Verma, S Vaidya, K Kalia… - Biomedicine & …, 2018 - Elsevier
Abstract Glucagon-like peptide (GLP)-1 is an incretin hormone exhibiting several
pharmacological actions such as neuroprotection, increased cognitive function, cardio …
pharmacological actions such as neuroprotection, increased cognitive function, cardio …
Glucagon-like peptide-1 analogues: an overview
V Gupta - Indian journal of endocrinology and metabolism, 2013 - journals.lww.com
Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2
diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide …
diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide …
Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future
S Kalra, MP Baruah, RK Sahay… - Indian journal of …, 2016 - journals.lww.com
Abstract Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control
through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of …
through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of …
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
JJ Meier - Nature Reviews Endocrinology, 2012 - nature.com
In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …
[HTML][HTML] A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
L Prasad-Reddy, D Isaacs - Drugs in context, 2015 - ncbi.nlm.nih.gov
The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …
used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight …
GLP-1 based therapy for type 2 diabetes
DK Arulmozhi, B Portha - European journal of pharmaceutical sciences, 2006 - Elsevier
Type 2 diabetes mellitus is a major and growing health problem throughout the world.
Current treatment approaches include diet, exercise, and a variety of pharmacological …
Current treatment approaches include diet, exercise, and a variety of pharmacological …
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
MS Fineman, BB Cirincione, D Maggs… - Diabetes, Obesity and …, 2012 - Wiley Online Library
Glucagon‐like peptide‐1 (GLP‐1), a gut‐derived hormone secreted in response to nutrients,
has several glucose and weight regulating actions including enhancement of glucose …
has several glucose and weight regulating actions including enhancement of glucose …
GLP-1 receptor agonists: a review of head-to-head clinical studies
JM Trujillo, W Nuffer, SL Ellis - Therapeutic advances in …, 2015 - journals.sagepub.com
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …
Comparison review of short-acting and long-acting glucagon-like peptide-1 receptor agonists
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) are useful tools for
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …
treating type 2 diabetes mellitus. In their recent position statement, the American Diabetes …
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents
B Gallwitz - Drugs, 2011 - Springer
Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …